Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer
Keywords: مهار کننده های تیروزین کیناز; ILD; interstitial lung disease; EGFR; epidermal growth factor receptor; TKIs; tyrosine-kinase inhibitors; PD-1; programmed cell death-1; NSCLC; non-small-cell lung cancer; RECIST; Response Evaluation Criteria in Solid Tumors; CT; chest computed tomography